keyword
MENU ▼
Read by QxMD icon Read
search

Indolent lymphoma

keyword
https://www.readbyqxmd.com/read/27913491/prognostic-factors-in-follicular-lymphoma-new-tools-to-personalize-risk
#1
Carla Casulo
Follicular lymphoma (FL) is the most common indolent lymphoma, and it has a long median overall survival (OS). However, the recent discovery of clinical and biological prognostic biomarkers in FL is shedding light on FL heterogeneity and the need for a precise and risk-stratified individual approach at diagnosis and relapse. Many FL patients who are asymptomatic with indolent disease can be vulnerable to the toxicity, emotional distress, and financial burden of overtreatment. Yet a subset of FL patients develop chemoresistance to standard chemoimmunotherapy, experience transformation to aggressive lymphoma and rapid progression, and represent the population most in need of novel therapies and curative approaches...
December 2, 2016: Hematology—the Education Program of the American Society of Hematology
https://www.readbyqxmd.com/read/27900638/bendamustine-plus-rituximab-for-previously-untreated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-or-mantle-cell-lymphoma-a-multicenter-phase-ii-clinical-trial-in-japan
#2
Michinori Ogura, Kenichi Ishizawa, Dai Maruyama, Naokuni Uike, Kiyoshi Ando, Koji Izutsu, Yasuhito Terui, Yoshitaka Imaizumi, Kunihiro Tsukasaki, Kenshi Suzuki, Tohru Izumi, Kensuke Usuki, Tomohiro Kinoshita, Masafumi Taniwaki, Nobuhiko Uoshima, Junji Suzumiya, Mitsutoshi Kurosawa, Hirokazu Nagai, Toshiki Uchida, Noriko Fukuhara, Ilseung Choi, Ken Ohmachi, Go Yamamoto, Kensei Tobinai
A Phase II, multicenter clinical trial of bendamustine plus rituximab (BR) regimen was conducted in previously untreated patients with high-tumor-burden indolent B-cell non-Hodgkin lymphoma (B-NHL) and previously untreated elderly patients with mantle cell lymphoma (MCL) in Japan. Bendamustine 90 mg/m(2)/day on days 1 and 2, as well as rituximab 375 mg/m(2) on day 1 were administered intravenously up to six cycles. The primary endpoint was the complete response (CR) rate as assessed by the International Workshop Response Criteria (1999)...
November 29, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27900446/health-related-quality-of-life-and-symptoms-in-patients-with-rituximab-refractory-indolent-non-hodgkin-lymphoma-treated-in-the-phase-iii-gadolin-study-with-obinutuzumab-plus-bendamustine-versus-bendamustine-alone
#3
Bruce D Cheson, Peter C Trask, John G Gribben, Natalie Dimier, Eva Kimby, Pieternella J Lugtenburg, Catherine Thieblemont, Elisabeth Wassner-Fritsch, Aino Launonen, Laurie H Sehn
We present health-related quality of life (HRQoL) data from GADOLIN, comparing bendamustine (B) alone or combined with obinutuzumab (G-B) in rituximab-refractory indolent non-Hodgkin lymphoma patients. The Functional Assessment of Cancer Treatment-Lymphoma (FACT-Lym) questionnaire was administered on day 1 of cycles 1, 3, and 5 during treatment, at end of induction (EOI), bi-monthly for 2 years during maintenance/follow-up, and annually during extended follow-up until progression/death. Time to first ≥6-point worsening from baseline in the FACT-Lym trial outcome index (TOI) was estimated...
November 30, 2016: Annals of Hematology
https://www.readbyqxmd.com/read/27896571/erratum-to-japanese-phase-ii-study-of-rituximab-maintenance-for-untreated-indolent-b-cell-non-hodgkin-lymphoma-with-high-tumor-burden
#4
Tadahiko Igarashi, Michinori Ogura, Kuniaki Itoh, Masafumi Taniwaki, Kiyoshi Ando, Yoshiaki Kuroda, Kazuhito Yamamoto, Naokuni Uike, Akihiro Tomita, Hirokazu Nagai, Mitsutoshi Kurosawa, Shigeo Mori, Shigeru Nawano, Takashi Terauchi, Yasuo Ohashi, Kensei Tobinai
No abstract text is available yet for this article.
November 28, 2016: International Journal of Hematology
https://www.readbyqxmd.com/read/27891267/marginal-zone-lymphoma-complicated-by-protein-losing-enteropathy
#5
Nadine Stanek, Peter Bauerfeind, Guido Herzog, Henriette Heinrich, Matthias Sauter, Daniela Lenggenhager, Cäcilia Reiner, Markus G Manz, Jeroen S Goede, Benjamin Misselwitz
Protein losing enteropathy (PLE) refers to excessive intestinal protein loss, resulting in hypoalbuminemia. Underlying pathologies include conditions leading to either reduced intestinal barrier or lymphatic congestion. We describe the case of a patient with long-lasting diffuse abdominal problems and PLE. Repetitive endoscopies were normal with only minimal lymphangiectasia in biopsies. Further evaluations revealed an indolent marginal zone lymphoma with minor bone marrow infiltration. Monotherapy with rituximab decreased bone marrow infiltration of the lymphoma but did not relieve PLE...
2016: Case Reports in Hematology
https://www.readbyqxmd.com/read/27879257/a-phase-ii-study-of-rituximab-plus-lenalidomide-for-mucosa-associated-lymphoid-tissue-lymphoma-malt-lymphoma
#6
Barbara Kiesewetter, Ella Willenbacher, Wolfgang Willenbacher, Alexander Egle, Peter Neumeister, Daniela Voskova, Marius Erik Mayerhoefer, Ingrid Simonitsch-Klupp, Thomas Melchardt, Richard Greil, Markus Raderer
Chemotherapy-containing regimens are effective for the treatment of advanced MALT lymphoma but due to the indolent course of this disease investigating the use of immunomodulatory, chemotherapy-free strategies appears reasonable. Based on the activity of lenalidomide (LEN) monotherapy for MALT lymphoma and promising results with LEN plus rituximab (R) in several B-cell malignancies, we have studied this combination for MALT lymphoma. In this multicenter phase II study (AGMT MALT-2), patients received R 375 mg/m2 d1 and LEN 20 mg d1-21 every four weeks...
November 22, 2016: Blood
https://www.readbyqxmd.com/read/27872742/systemic-front-line-therapy-of-follicular-lymphoma-when-to-whom-and-how
#7
REVIEW
Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca
The natural history of follicular lymphoma is usually characterized by an indolent course with a high response rate to the first line therapy followed by recurrent relapses, with a time to next treatment becoming shorter after each subsequent treatment line. More than 80% of patients have advanced stage disease at diagnosis. The time of initiation and the nature of the treatment is mainly conditioned by symptoms, tumor burden, lymphoma grading, co-morbidities and patients preference. A number of clinical and biological factors have been determined to be prognostic in this disease, but the majority of them could not show to be predictive of response to treatment, and therefore can't be used to guide the treatment choice...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27872741/novel-drugs-in-follicular-lymphoma
#8
REVIEW
Antonella Anastasia, Giuseppe Rossi
Follicular lymphoma(FL) is the most common indolent non-Hodgkin lymphoma and constitutes 15% to 30% of lymphoma diagnoses. The natural history of the disease is characterized by recurrent relapses and progressively shorter remissions with a median survival of 10yrs. The impossibility of achieving a definite cure, have prompted investigations into the possible role of more active and less toxic strategies with innovative therapeutic agents. Recently Casulo et al. demonstrated that approximately 20% of patients with FL relapse within two years after achieving remission with R-CHOP and have a poor prognosis...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27872740/follicular-lymphoma-a-clinicopathological-analysis-from-a-tertiary-care-institute-in-southern-india
#9
Mary Theresa Sylvia, Biswajit Dey, Debdatta Basu, Sajini Elizabeth Jacob, Rakhee Kar, Biswajit Dubashi
INTRODUCTION: Follicular lymphoma (FL) is an indolent lymphoproliferative disorder of B-cells with variable clinical behavior. It is the second most common subtype of Non-Hodgkin lymphoma in western countries but reported to have a lower incidence in Asia. MATERIALS AND METHODS: Cases of FL diagnosed in the Department of Pathology of our Institute from January 2009 to June 2015 were included in the study. The clinicopathological parameters including staging, histological details, and immunohistochemical markers CD20, CD10 and BCL-2 were recorded in all the cases...
2016: Mediterranean Journal of Hematology and Infectious Diseases
https://www.readbyqxmd.com/read/27866584/lymphoma
#10
REVIEW
Emiliano N Mugnaini, Nilanjan Ghosh
Lymphomas may be broadly divided into non-Hodgkin (90%) and Hodgkin (10%) types. Most lymphomas (90%) are of B cell origin but can also be T cell or natural killer cell. Clinical management of indolent and aggressive lymphomas is different. Aggressive lymphomas are more dangerous if left untreated yet a higher cell proliferation rate also renders them more chemosensitive, so they are managed with curative intent. Indolent lymphomas are, for the most part, incurable, such that quality of life must be balanced against toxicity of treatment in deciding when and how to treat...
December 2016: Primary Care
https://www.readbyqxmd.com/read/27831904/distinct-biological-subtypes-and-patterns-of-genome-evolution-in-lymphoma-revealed-by-circulating-tumor-dna
#11
Florian Scherer, David M Kurtz, Aaron M Newman, Henning Stehr, Alexander F M Craig, Mohammad Shahrokh Esfahani, Alexander F Lovejoy, Jacob J Chabon, Daniel M Klass, Chih Long Liu, Li Zhou, Cynthia Glover, Brendan C Visser, George A Poultsides, Ranjana H Advani, Lauren S Maeda, Neel K Gupta, Ronald Levy, Robert S Ohgami, Christian A Kunder, Maximilian Diehn, Ash A Alizadeh
Patients with diffuse large B cell lymphoma (DLBCL) exhibit marked diversity in tumor behavior and outcomes, yet the identification of poor-risk groups remains challenging. In addition, the biology underlying these differences is incompletely understood. We hypothesized that characterization of mutational heterogeneity and genomic evolution using circulating tumor DNA (ctDNA) profiling could reveal molecular determinants of adverse outcomes. To address this hypothesis, we applied cancer personalized profiling by deep sequencing (CAPP-Seq) analysis to tumor biopsies and cell-free DNA samples from 92 lymphoma patients and 24 healthy subjects...
November 9, 2016: Science Translational Medicine
https://www.readbyqxmd.com/read/27825469/the-role-of-stem-cell-transplantation-in-waldenstrom-s-macroglobulinemia
#12
REVIEW
Rajshekhar Chakraborty, Eli Muchtar, Morie A Gertz
Waldenstrom's macroglobulinemia (WM) is an indolent B-cell lymphoma, which is highly chemosensitive, with an overall response rate over 90% to novel agents. However, most patients eventually relapse after response to first-line chemotherapy, necessitating further treatment. The possibility of long-lasting remission after high-dose cytotoxic chemotherapy followed by stem cell rescue is high in WM due to the chemosensitive nature of the disease and lower proliferative activity compared to multiple myeloma. In this paper, we have reviewed current evidence on autologous (auto-) and allogeneic (allo-) stem cell transplantation (SCT) in WM...
June 2016: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/27825461/epigenomics-in-waldenstrom-s-macroglobulinaemia
#13
REVIEW
Antonio Sacco, Adriano Fenotti, Stefano Bazzana, Luisa Imberti, Giuseppe Rossi, Christopher J Patterson, Steven P Treon, Irene M Ghobrial, Aldo M Roccaro
Epigenomics refers to study of the epigenome, which represents changes in gene expression that are not induced by DNA sequence aberrations. For instance, DNA methylation, histone acetylation and microRNAs may modulate gene expression without altering the gene sequence. Waldenström's macroglobulinaemia (WM) is a low-grade B-cell lymphoma, classified as lymphoplasmacytic lymphoma, characterized by the presence of clonal lymphoplasmacytic cells in the bone marrow and serum monoclonal immunoglobulin-M in the circulation...
June 2016: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/27820922/a-multicenter-phase-ii-study-of-twice-weekly-bortezomib-plus-rituximab-in-patients-with-relapsed-follicular-lymphoma-long-term-follow-up
#14
Alessia Bari, Raffaella Marcheselli, Luigi Marcheselli, Isabel Alvarez, Samantha Pozzi, Paola Ferri, Antonio Lazzaro, Alberto Fragasso, Santo Neri, Luca Baldini, Angelo Michele Carella, Francesco Angrilli, Roberto Guariglia, Gabriele Buda, Caterina Stelitano, Stefano Sacchi
Single-agent bortezomib (B) has shown activity in heavily pretreated patients with relapsed/refractory indolent lymphoma. On the basis of these findings, we performed a phase II study of B combined with rituximab (R) in patients with relapsed follicular lymphoma (FL). Forty-five patients with fairly good prognostic profiles were enrolled from 2007 to 2011 and received a total of 6 cycles of the B+R combination. The endpoints were the overall response rate (ORR), progression-free survival (PFS), duration of remission (DoR), overall survival (OS), and toxicity evaluation...
November 4, 2016: Acta Haematologica
https://www.readbyqxmd.com/read/27819641/an-unwonted-clinicopathological-subtype-of-thyroid-primary-lymphoma
#15
Mihai Radu Diaconescu, Ioan Costea, Mihai Glod, Smaranda Diaconescu
Primary thyroid lymphomas account for less than 5% of all thyroid malignancies and the majority of cases concern non- Hodgkin's lymphoma of B and T-cell origin as well as Hodgkin's lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma are a relatively recently described subset of low grade B-cell non-Hodgkin's lymphoma representing between 6 and 27% of the patients with thyroid lymphomas. These cases occur usually in patients with Hashimoto's thyroiditis having a long indolent course and delayed diagnosis, actually benefit from several therapeutic opportunities among them even surgery and a favorable prognostic...
2016: Chirurgia
https://www.readbyqxmd.com/read/27813427/is-there-a-role-for-a-maintenance-rituximab-in-indolent-lymphoproliferative-diseases-other-than-follicular-lymphoma
#16
Alden A Moccia, Emanuele Zucca, Michele Ghielmini
Rituximab (R) is an anti-CD20 monoclonal antibody which has become an essential component for the treatment of B-cell lymphomas. When associated to chemotherapy it improves the outcome of the patients with diffuse large B-cell lymphoma, follicular lymphoma, and other lymphoproliferative diseases in comparison to chemotherapy alone. For patients with newly diagnosed follicular lymphoma achieving at least a partial response to initial immuno-chemotherapy, maintenance R was associated with an improvement in progression-free survival and a meta-analysis of randomized maintenance trials suggests an overall survival advantage...
January 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/27807508/occurrence-of-lymphoma-in-non-gonadal-organ-during-pregnancy-a-report-on-four-cases-and-literature-review
#17
Da-Lin Gao, Qian-Qian Fu, Tian-Tian Zhang, Lin Sun, Yi Pan, Qiong-Li Zhai
Lymphoma rarely occurs during pregnancy, making this condition difficult to define. Lymphomas that occur in reproductive organs during pregnancy exhibit unique clinical characteristics. Among the limited cases, non-Hodgkin's lymphoma (NHL) shows a considerably higher incidence rate than Hodgkin's lymphoma (HL); NHL also displays clinical characteristics, such as high aggressiveness, advanced stage, and poor outcome. This study reports on four cases of lymphomas in non-gonadal organs (HL, n=2; NHL, n=2) during pregnancy...
September 2016: Cancer Biology & Medicine
https://www.readbyqxmd.com/read/27787356/pegylated-liposomal-encapsulated-doxorubicin-in-cutaneous-composite-lymphoma-a-case-report
#18
Uwe Wollina, Dana Langner, Gesina Hansel, Gunter Haroske
BACKGROUND: Cutaneous composite lymphomas are very rare. Their treatment depends upon the different contributing lymphoma entities. Peripheral T-cell lymphoma, not otherwise specified, (PTCL-NOS) represents an aggressive lymphoma subtype. Follicular cutaneous B-cell lymphoma (FCBCL) runs an indolent course. Treatment with pegylated liposomal encapsulated doxorubicin (PLE-DOXO) has yet not been reported in this entity. CASE PRESENTATION: A 73-year-old male patient presented with 3 rapidly growing, painful nodules on his left leg...
October 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27784957/antiviral-therapy-of-hepatitis-c-as-curative-treatment-of-indolent-b-cell-lymphoma
#19
REVIEW
Michele Merli, Giuseppe Carli, Luca Arcaini, Carlo Visco
The association of hepatitis C virus (HCV) and B-cell non-Hodgkin lymphomas (NHL) has been highlighted by several epidemiological and biological insights; however the most convincing evidence is represented by interventional studies demonstrating the capability of antiviral treatment (AT) with interferon (IFN) with or without ribavirin to induce the regression of indolent lymphomas, especially of marginal-zone origin. In the largest published retrospective study (100 patients) the overall response rate (ORR) after first-line IFN-based AT was 77% (44% complete responses) and responses were sustainable (median duration of response 33 mo)...
October 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/27781290/low-dose-radiotherapy-in-diffuse-large-b-cell-lymphoma
#20
Carlo Furlan, Vincenzo Canzonieri, Michele Spina, Mariagrazia Michieli, Anna Ermacora, Roberta Maestro, Sara Piccinin, Riccardo Bomben, Michele Dal Bo, Marco Trovo, Valter Gattei, Umberto Tirelli, Giovanni Franchin, Pietro Bulian
Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions...
October 25, 2016: Hematological Oncology
keyword
keyword
99818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"